SCHEMBL20476331

SCHEMBL20476331

CCNc1cc(CC)nc(Cl)n1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.47
LMNA P02545 1/20 0.45
MAPT P10636 1/20 0.41
KMT2A Q03164 1/20 0.41
CYP1A2 P05177 2/20 0.36
PGK1 P00558 4/20 0.35
KCNH2 Q12809 3/20 0.35
CACNA1C Q13936 2/20 0.35
SCN5A Q14524 2/20 0.35
FABP4 P15090 1/20 0.34
EGFR P00533 1/20 0.33
NOS3 P29474 1/20 0.33
NOS2 P35228 1/20 0.33
ESR2 Q92731 1/20 0.33
GSK3B P49841 1/20 0.33
MAP4K2 Q12851 1/20 0.33
NPY1R P25929 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11689561 0.86 ESR1 (0.61) ESR1LMNAMAPTKMT2APGK1
SCHEMBL23588568 0.82 ESR1 (0.40) ESR1LMNAMAPTKMT2ACYP1A2
SCHEMBL10093922 0.80 ESR1 (0.50) ESR1LMNAMAPTKMT2APGK1
SCHEMBL12309955 0.79 NOS3 (0.43) ESR1LMNAMAPTKMT2AFABP4
SCHEMBL28230769 0.79 ESR1 (0.39) ESR1LMNAMAPTKMT2ACYP1A2
SCHEMBL20476323 0.78 MAPT (0.50) ESR1LMNAMAPTKMT2APGK1
SCHEMBL9842958 0.77 ESR1 (0.38) ESR1KMT2ACYP1A2ESR2
SCHEMBL2623105 0.74 ESR1 (0.42) ESR1PGK1KCNH2CACNA1CSCN5A
SCHEMBL11364615 0.74 ESR1 (0.44) ESR1LMNAMAPTKMT2APGK1
SCHEMBL25145081 0.73 LMNA (0.44) ESR1LMNAMAPTKMT2ACYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11078165-B2 Compounds for treating tuberculosis NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2021-08-03 US disclosed
US-20200231550-A1 COMPOUNDS FOR TREATING TUBERCULOSIS NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2020-07-23 US disclosed
WO-2018151681-A1 COMPOUNDS FOR TREATING TUBERCULOSIS NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2018-08-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11078165-B2 Compounds for treating tuberculosis ATP5ME, ATP5MG, ATP5F1D ESR1 2488/4885LMNA 3226/4885MAPT 2750/4885
US-20200231550-A1 COMPOUNDS FOR TREATING TUBERCULOSIS ATP5ME, ATP5MG, ATP5F1D ESR1 2488/4885LMNA 3226/4885MAPT 2750/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.